Exploration of VEGF expression in paediatric high grade glioma and diffuse intrinsic pontine glioma using 89Zirconium-bevacizumab imaged by PET

Exploration of VEGF expression in paediatric high grade glioma and diffuse intrinsic pontine glioma using 89Zirconium-bevacizumab imaged by PET - 89Zr-Bevacizumab PET in pHGG & DIPG

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38105

Enrollment

Registered

2011-08-23

Start date

2011-11-15

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brainstem tumor high grade glioma

Interventions

89-Zr bevacizumab once

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: - DIPG (MRI confirmed, biopsy not required) after radiotherapy - De novo biopsy proven HGG with minimal residual tumor of 5 mm in each dimension - pHGG & DIPG patients with progressive disease after radiotherapy - Age between 4 and 18 years - Able to lay down quiet for 30 minutes

Exclusion criteria

Exclusion criteria: - Chemotherapy or radiotherapy in the past two weeks - Previous administration of bevacizumab or another anti-VEGF drug - Known hypersensitivity against humanized monoclonal antibodies - Neurofibromatosis type I

Design outcomes

Secondary

Measure	Time frame
- Optimal moment of scanning obtained by five patients with positive 89Zr-bevacizumab uptake - Body biodistribution and dosimetry of 89Zr-bevacizumab	—

Primary

Measure	Time frame
VEGF-expression measured by Standard Uptake Values of 89Zr-Bevacizumab in pHGG and DIPG	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)